Production (Stage)
Cartesian Therapeutics, Inc.
RNAC
$10.32
-$0.10-0.96%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 31.91% | 49.64% | -62.40% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 31.91% | 49.64% | -62.40% | -- | -- |
| Cost of Revenue | -11.55% | -31.61% | -57.21% | -- | -- |
| Gross Profit | 48.26% | 84.89% | -117.44% | -- | -- |
| SG&A Expenses | -24.51% | -13.59% | -4.69% | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.79% | -25.37% | -43.49% | -- | -- |
| Operating Income | 35.06% | 51.59% | -36.21% | -- | -- |
| Income Before Tax | 86.12% | 67.69% | -12,487.26% | -- | -- |
| Income Tax Expenses | 101.51% | 101.51% | -3,019.87% | -- | -- |
| Earnings from Continuing Operations | 84.97% | 64.76% | -16,364.63% | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 84.97% | 64.76% | -16,364.63% | -- | -- |
| EBIT | 35.06% | 51.59% | -36.21% | -- | -- |
| EBITDA | 37.39% | 52.60% | -41.39% | -- | -- |
| EPS Basic | 97.03% | 76.57% | -529.76% | -- | -- |
| Normalized Basic EPS | 97.08% | 90.89% | -318.42% | -- | -- |
| EPS Diluted | 96.94% | 76.47% | -529.94% | -- | -- |
| Normalized Diluted EPS | 96.97% | 90.79% | -318.92% | -- | -- |
| Average Basic Shares Outstanding | 326.63% | 233.80% | 217.83% | -- | -- |
| Average Diluted Shares Outstanding | 331.72% | 238.96% | 224.77% | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |